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Abstract
Myofibrillar myopathies (MFM) are a group of disorders associated with mutations in DES, 
CRYAB, MYOT, ZASP, FLNC, or BAG3 genes and characterized by disintegration of myofibrils 
and accumulation of degradation products into intracellular inclusions. We retrospectively 
evaluated 53 MFM patients from 35 Spanish families. Studies included neurologic exam, muscle 
imaging, light and electron microscopic analysis of muscle biopsy, respiratory function testing and 
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cardiologic work-up. Search for pathogenic mutations was accomplished by sequencing of coding 
regions of the six genes known to cause MFM. Mutations in MYOT were the predominant cause 
of MFM in Spain affecting 18 of 35 families, followed by DES in 11 and ZASP in 3; in 3 families 
the cause of MFM remains undetermined. Comparative analysis of DES, MYOT and ZASP 
associated phenotypes demonstrates substantial phenotypic distinctions that should be considered 
in studies of disease pathogenesis, for optimization of subtype-specific treatments and 
management, and directing molecular analysis.
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1. Introduction
Myofibrillar myopathies (MFMs) are a group of genetically heterogenic disorders having in 
common myopathological features of disintegration of myofibrils and accumulation of 
degradation products into inclusions containing desmin and other myofibrillar or ectopic 
proteins [1]. The proteins involved in MFM vary significantly in their structure and function. 
Desmin is a muscle-specific type III intermediate filament protein interlinking myofibrils at 
the level of the Z-disc and connecting them to other cellular organelles thus maintaining the 
structural and functional integrity of the muscle cell [2]. αB-crystallin belongs to the small 
heat-shock protein family and serves in the muscle as a chaperone for desmin and other 
proteins assuring their normal folding [3]. Filamin C cross-links actin at the Z-disc level, 
binds to other Z-disc proteins and interacts with the dystrophin–dystroglycan complex at the 
sarcolemma [4]. BAG3 participates in antiapoptotic pathways and exerts co-chaperon 
activity by binding to Hsp70/HSC70 [5].
Myotilin is a sarcomeric Z-disc protein expressed strongly in skeletal and weakly in cardiac 
muscle [6]. Myotilin plays a significant role in sarcomere assembly, acting together with α-
actinin and filamin C to cross-link actin into tightly packed bundles. The resulting structures 
support the integrity of the contracting muscle cell [7]. Myotilin is encoded by a single copy 
gene (MYOT, TTID) located on chromosome 5q31 [8,9]. Mutations in MYOT were 
originally described in autosomal dominant limb girdle muscular dystrophy type 1A 
(LGMD1A) [10], and subsequently identified in a subgroup of patients with myofibrillar 
myopathy [11] as well as a family with spheroid body myopathy [12]. Considering 
pathological similarity of LGMD 1A [13] and spheroid body myopathy to MFM, these 
disorders are now classified as MFM.
ZASP (Z band alternatively spliced PDZ-containing protein), also known as LIM-domain-
binding-3 (LDB3), CYPHER or Oracle, is a Z-disc-associated protein of skeletal and cardiac 
muscles. The N-terminal PDZ domain interacts with the C terminus of α-actinin-2, the 
major component of the Z-disc [14,15]. ZASP also interacts with filamin C and calsarcin, 
both of which in turn bind to myotilin [16,17]. Mutations in human ZASP gene were 
discovered in patients suffering from dilated cardiomyopathy or left ventricular non-
compaction [18], and another set of ZASP mutations was identified in patients with MFM 
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[19]. One of these mutations was also identified in a large family originally reported by 
Markesbery et al. [20,21].
No systematic studies reflecting on the relative frequency and comparative phenotypic 
characteristics of various types of MFM in a single population have been conducted. This 
study is based on a nation-wide ascertainment and clinical, pathological and molecular 
analysis of MFM cases in Spain.
2. Materials and methods
2.1. Patient identification and evaluation
Patients with suspected MFM were systematically identified, examined and documented by 
the study participants within a timeframe of more than 10 years. Periodic patient follow-ups 
were conducted. Each member of an affected family was fully studied; most commonly, the 
first patient referred for a study was considered as index case. The following investigations 
were carried out in each patient: pedigree analysis, neurologic exam, including muscle 
strength assessment according to the Medical Research Council (MRC) grading scale, serum 
CK level assessment, electrophysiological studies that included nerve conduction tests and 
concentric needle EMG, respiratory function tests and cardiologic examination with 
electrocardiography and echocardiography. Muscle Computer tomography (CT) or Magnetic 
Resonance Images (MRI) were taken at mid-thigh and mid-calf levels. Time elapsed 
between the disease onset and the muscle imaging examination varied from 2 to 23 years. 
Diagnostic muscle biopsy was performed in each sporadic case and at least one patient per 
affected family. Histopathological diagnostic criteria were similar to those suggested earlier: 
alterations in trichromatically stained muscle sections consisting of intracellular 
accumulation of amorphous, hyaline, or granular material that represents ectopic protein 
deposits immunoreacting with desmin and ultrastructural analysis demonstrating 
myofibrillar degeneration and disintegration of the sarcomere [22,23]. Data on 22 of 53 
patients included in the present study have been described or briefly mentioned in previous 
publications [24–31].
2.2. Mutation screening and genotyping
Each index case was tested for the presence of mutations in the coding regions of DES, 
CRYAB, MYOT, ZASP, FLNC, and BAG3 genes known to cause MFM. The priorities for 
testing of individual genes were established based on clinical, muscle imaging and 
pathological analysis, which was a learning process that led eventually to a point at which 
the affected gene could be predicted with an almost 100% certainty.
PCR amplification with intronic primers constructed to amplify each exon was carried out 
by using an optimal procedure designed for each segment. The resulting DNA fragments 
were sequenced using BigDyeTerminatore™ protocol on an automated 3100 ABI Prism 
Genetic Analyzer (Applied Biosystems, Foster City, CA). Mutation identification was 
accomplished by aligning with database sequences (http://www.ncbi.nlm.nih.gov); positive 
and negative controls were included as part of each test.
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Three microsatellite markers (D5S2115, D5S479, D5S476) and four single nucleotide 
polymorphisms (SNP) located within a 4-centimorgan MYOT chromosomal region were 
typed in 16 patients and 48 Spanish control individuals. PCR amplification of microsatellite-
containing fragments was performed with primers, one of which was fluorescently labeled. 
Fragment analysis and sequencing for assessing the SNP phase were performed on an 
automated 3100 ABI Prism Genetic Analyzer.
Clinical, myopathological and molecular genetic studies were conducted under clinical 
protocols approved by the Institutional Review Boards of each participating institution; 
genetic testing was performed in a CLIA-certified laboratory at the Clinical Neurogenetics 
Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD.
2.3. Muscle imaging
Muscle imaging studies were performed by using Computed Tomography or Magnetic 
Resonance Imaging at mid-thigh and mid-calf levels in 36 patients (11 desminopathy, 17 
myotilinopathy, 5 zaspopathy, and three patients with no mutations in any of the genes 
known to cause MFM). The degree of muscle involvement was evaluated using a 5-point 
scale ranging from 0 to 4 as described [29].
2.4. Muscle biopsy
Open muscle biopsy was carried out for diagnostic purposes in each index case. Skeletal 
muscle tissue was obtained from a clinically affected muscle, or from a muscle showing 
involvement on muscle imaging studies. The samples were processed for routine 
histochemical tests and Congo red staining and immunohistochemistry by using commercial 
antibodies against myotilin, desmin, αB-crystallin, dystrophin, gelsolin and ubiquitin, and a 
mouse monoclonal anti-filamin C antibody kindly provided by Fürst and coworkers [32]. 
The source of antibodies we used is provided in Supplementary Table 1. A small sample of 
biopsy tissue was fixed in 2% glutaraldehyde, postfixed with 1% osmium tetroxide, and 
embedded in araldite. Ultrathin sections were stained with uranyl acetate and lead citrate and 
viewed with a JEOL 1011 electron microscope.
3. Results
3.1. Frequency and types of mutations identified in MFM genes
Mutations have been identified in DES, MYOT, or ZASP genes of 49 patients with clinical/
pathological diagnosis of definite MFM originating from 32 families (Table 1). Evaluation 
of the relative role of the set of genes causing MFM shows that mutations in MYOT were 
the predominant cause of MFM in Spain affecting 18 of 35 studied families, followed by 
DES in 11 families and ZASP in 3. No cases with mutations in CRYAB, BAG3, or FLNC 
have so far been found. In 3 families the cause of MFM remains unidentified. Of the MYOT 
mutations, p.Ser55Phe and p.Ser60Cys were the most common causes of myotilinopathy in 
this cohort found in 7 families each. DES p.Leu392Pro, p.Leu370Pro, and p.Pro419Ser have 
been identified in large families. This is the first report of ZASP p.Ala174Thr and 
p.Ala165Val mutations in Spanish MFM patients that were identified in one and two 
families, respectively.
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The pattern of inheritance was autosomal dominant in 20 of 35 affected families (Table 2). It 
was noticeable on comparison that a significant number of MYOT patients (9 of 18), 
especially those carrying the p.Ser55Phe mutation, did not have family history of the 
disease. Genotyping of two families and 4 sporadic cases carrying the p.Ser55Phe mutation 
identified a core haplotype consisting of alleles168–125-Phe-G-C-161 that is shared by eight 
patients. This haplotype was not found in controls. Subsequent inquiry established that all 
haplotype-sharing patients have arrived in Barcelona area from Murcia, a Southern region of 
Spain, and presumably are members of a founder population. There was a massive 
immigration to Catalonia from southern Spain during the second half of the 20th century. 
Seven patients carrying the second frequent p.Ser60Cys mutation were similarly genotyped 
but did not show a common haplotype.
3.3. Clinical manifestations
The age of disease onset was significantly earlier in patients with DES mutations (mean, 28 
years; 95% confidence interval [CI] 15.9–36.1) as compared to MYOT (mean, 58; 95% CI 
49.3–64.7) or ZASP (mean 56; 95% CI 48.9–63.1). This characterizes MYOT- and ZASP-
associated myopathy as a late-onset disease.
Bilateral weakness in the distal lower limb muscles manifesting as foot drop was the 
predominant initial symptom; proximal muscle weakness leading to difficulties with 
standing up, climbing stairs or rising arms was the initial sign in only a few patients (3 
MYOT and 1 ZASP patients). Cardiopathy was the initial clinical manifestation in 8 patients 
with DES and none of the MYOT or ZASP patients (Table 2).
In the course of illness, most MFM patients of each subtype developed weakness in both 
distal and proximal leg muscles and in the majority of patients muscle weakness extended to 
the upper limbs (Table 2). Facial, neck flexor and trunk muscles were involved quite 
frequently in patients with DES but not MYOT or ZASP mutations (Table 2). Most 
significantly, 16 of 18 patients with DES mutations developed cardiopathy in the course of 
illness, while only 1 elderly patient with MYOT and 1 with a ZASP mutation had suspected 
cardiac involvement, most likely unrelated to MFM. Among patients with DES mutations, 
atrioventricular conduction blocks were recorded in 16 (89%), episodes of tachyarrhythmia 
in 12 patients (67%) and 10 patients developed heart failure as a result of dilated, restrictive 
or hypertrophic cardiomyopathy confirmed by echocardiographic examination. The disease 
outcome in these patients was most severe: three DES patients died suddenly at an early age 
and two received a heart transplant (Table 2). Five MYOT patients died between the ages of 
82 and 86 years. Nine patients with DES mutations had restrictive ventilatory insufficiency, 
while only 3 of MYOT and none of ZASP patients showed signs of respiratory weakness.
Muscle imaging disclosed characteristic patterns of muscle involvement (Fig. 1, Table 2). In 
patients with DES mutations, the earliest and most consistently affected muscle at mid-thigh 
is semitendinosus (11/11 patients), followed by sartorius and gracilis. The 
semimembranosus shows minimal damage. On the contrary, the semimembranosus, hip 
adductors and biceps femoris were initially affected in MYOT (15/17, 15/17 and 16/17, 
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respectively), and ZASP (4/5, 4/5 and 3/5) subtypes, whereas the semitendinosus remained 
spared. Of the distal muscles, the earliest abnormalities in DES patients occurred in the 
peroneal muscles (11/11 patients), followed by tibialis anterior and the posterior 
compartment muscles (soleus, medial, and lateral gastrocnemius), while in MYOT and 
ZASP cases the first affected was soleus (16/17 and 5/5 patients) and medial gastrocnemius 
and subsequently the anterior tibialis and the peroneal group.
Creatine kinase level was normal to moderately elevated and EMG examination shows signs 
of myopathy with spontaneous activity at rest manifested by positive sharp waves, 
fibrillation potentials, and high bizarre discharges in most cases. None of the studied patients 
had peripheral nerve conduction abnormality, except for a single patient with a MYOT 
mutation.
3.4. Myopathology
Features shared by DES, MYOT and ZASP subtypes include nonspecific myopathic changes 
ranging from mild variation in the fiber size and increased number of internal nuclei to more 
advanced degenerative abnormalities comprising muscle fiber atrophy and hypertrophy, fiber 
splitting, and fibro-fatty tissue proliferation (Table 3, Fig. 2). Nuclear clumps are common in 
patients with MYOT and ZASP mutations (16/20 and 3/3) but rare in DES patients (3/12) 
(Table 3, Fig. 2). MYOT subtype is characterized by a more frequent presence of muscle 
fiber necrosis with phagocytosis (13/20) and in some cases small inflammatory infiltrates 
(6/20). Collections of cytoplasmic bodies and some nemaline-like bodies appearing as red 
granules on modified trichrome stain are frequent in both MYOT and ZASP (18/20 and 3/3) 
but rare in DES patients (3/12) (Table 3, Fig. 2). In addition, spheroid inclusion bodies 
stained green on modified trichrome were observed in most MYOT and ZASP cases (18/20 
and 3/3), but infrequently in DES (2/12). Rimmed vacuoles were present in all studied cases, 
their number and size being larger in the MYOT and ZASP than DES. Patients with MYOT 
and ZASP subtypes had in addition a comparatively greater number of non-rimmed vacuoles 
(Fig. 2).
Intracytoplasmic inclusions, the morphological hallmark of MFM, are present in each 
studied case, but their morphological characteristics vary. In DES cases the inclusions 
appear as thin patches or spider-web-like formations under the sarcolemma or within the 
cytoplasm stained eosinophilic and less frequently basophilic on H&E, and green, bluish or 
red-bluish on modified trichrome stain (Fig. 2). They coexist with well demarcated inclusion 
bodies in a few cases. Congophilia is lacking or faint. Oxidative enzyme activity is absent in 
the inclusions, resulting in “rubbed-out” appearance in the affected areas of the muscle fiber 
(11/12 of DES patients, Table 3 and Fig. 2C). Core-like lesions are seen in the majority of 
cases (Table 3). Proteinaceous deposits forming sprout networks and less frequently granular 
or dot-like aggregates strongly react with antibodies against desmin, αB-crystallin, 
dystrophin and filamin C, and weakly with ubiquitin and myotilin (Fig. 2D).
In patients carrying MYOT and ZASP mutations, muscle fibers contain more dense hyaline 
material bright pink on H&E and blue/purple on modified trichrome stain (Fig. 2E and I). 
Round or spheroid inclusion bodies were observed in the majority of patients. Strong 
congophilia is a prominent feature. Inclusions similar to those seen in DES cases are also 
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present. Irregular core-like lesions, generally surrounded by increased oxidative enzyme 
activity are encountered in all samples whereas “rubbed-out” fibers are rare (Fig. 2G and K). 
The inclusions show prominent desmin, αB-crystallin, dystrophin, myotilin (Fig. 2H and L), 
ubiquitin, and filamin C immunoreactivity.
At EM investigation, initial changes in DES cases feature small electron-dense dots in close 
proximity to the Z-lines, while larger dappled reticular granulofilamentous structures are 
seen disrupting the Z-lines in a more advanced stage (Fig. 3A–C). With disease progression, 
coarse granulofilamentous material covers larger areas centrally and under the plasma 
membrane. Groups of normally looking mitochondria are positioned between and sometimes 
within the granulofilamentous masses. Z-line streaming, glycogen granules and autophagic 
vacuoles containing myelin figures are observed in most DES cases. Studies of an explanted 
heart of a patient with DES mutation showed lesions identical to those observed in skeletal 
muscle (Fig. 3D). In a single patient, 15–18 nm tubulofilaments, a filamentous body and 
dense globoid inclusions were observed in a totaly degenerated fiber. In patients with MYOT 
and ZASP mutations, early lesions consist of streaming and widened Z-lines. In more 
severely affected fiber areas, filamentous bundles of Z-disc origin and fine filamentous 
debris are accumulating within the cytoplasm and subsarcolemmal regions and frequently 
form globoid inclusions (Fig. 3E, F, I and J). Collections of 15–18 nm tubulofilaments were 
frequently observed in MYOT (14/17 and 2/2 in Table 3, Fig. 3H). Typical nemaline bodies 
were observed in one MYOT case and were conspicuous in all ZASP cases. Intranuclear 
rods were observed in four ZASP samples (data not shown).
Mitochondria are absent within the disorganized masses but present at their periphery (Fig. 
3F). Autophagic vacuoles (Fig. 3L) and small foci containing granulofilamentous material 
similar to those described in the DES cases are also observed in some MYOT and ZASP 
patients.
3.5. Patients with no mutations
Four patients from three families were negative for mutations in any of the known MFM 
causative genes. The age of onset in these patients varied from 40 to 69 years. Three 
presented with distal weakness of lower limbs and the remaining one had proximal 
weakness at onset. One patient developed respiratory insufficiency but none had cardiopathy 
or peripheral neuropathy. Muscle imaging performed in three cases showed a pattern of 
muscle involvement similar to that observed in patients carrying mutations in MYOT or 
ZASP genes. Muscle biopsies of three patients showed features similar to those described 
for MYOT and ZASP mutations. However, the numbers of muscle fibers containing 
myofibrillar inclusions were less numerous than in MYOT or ZASP cases.
4. Discussion
MFMs are an expanding and increasingly recognized group of muscular disorders caused by 
mutations in DES, CRYAB, MYOT, ZASP, FLNC, or BAG3 genes. A comprehensive study 
of 53 patients from 35 Spanish families molecularly identified as MFM and representing 
three gene-associated MFM subtypes allows to identify subtype-specific clinical, 
myopathological and genetic features. Evaluation of the relative frequency of these three 
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subtypes in Spain shows that mutations in MYOT were the predominant cause of MFM, 
followed by DES and ZASP. This ratio indicates that the late-onset types of MFM with 
mutations in MYOT and ZASP are a relatively frequent cause of MFM in Spain which 
correlates with a previous report on the subtype distribution in the largest known series of 63 
MFM patients studied in the Mayo Clinic [23]: DES 6%, MYOT 10%, CRYAB 3%, ZASP 
15%, FLNC 3%, and mutations not found in 62%. Data presented here suggest that a MYOT 
p.Ser55Phe mutation may have spread in the founder population of Murcia of South-Eastern 
Spain and resulted in a relatively increased frequency of the MYOT associated subtype. A 
similar explanation has previously been suggested for the increased prevalence of C-
filaminopathy in Germany [33] and desminopathy in Poland [25].
Our analysis identifies profound clinical differences between the groups of patients with 
relatively early-onset MFM caused by DES mutations and late-onset subtypes associated 
with mutations in MYOT and ZASP. Patients with DES mutations show a much wider 
distribution of muscle weakness spreading to the facial, bulbar, neck and trunk muscles in 
the advanced illness; these groups of muscles are rarely involved in MYOT and ZASP. 
Muscle imaging studies show a selective involvement of peroneus, semitendinosus and 
sartorius muscles at the disease onset in patients with DES mutations, while soleus and 
semimembranosus are seen the first to be involved in MYOT and ZASP cases. We thus 
confirm the conclusions regarding the differential topography of muscle involvement made 
previously [29,34]. Cardiopathy and respiratory weakness are frequently present in the early 
phase of desminopathy and lead to incapacity and death at young age, while these 
complications are rare in the late-onset MYOT and ZASP forms. Peripheral neuropathy 
reported in some cases of myotilinopathy and ZASPopathy [11,19] is not a consistent 
feature in our patients. A later age of disease onset predicts a more favorable disease 
outcome. Indeed, the disease progression in both MYOT and ZASP patients was very slow, 
they remained ambulatory until very late age.
Clinical analysis is corroborated by myopathological findings demonstrating that even 
though there are similarities between the subtypes, especially in muscle fibers with advanced 
destructive lesions, there are important distinguishing features. Characteristic hyaline 
inclusions corresponding at the ultrastructural level to fragmented and compacted filaments 
in MYOT and ZASP specimens are distinct from non-hyaline inclusions seen at sites 
occupied by granulofilamentous material in DES-associated cases. Vacuolar changes are 
most prominent in MYOT and ZASP patients. “Rubbed-out” fibers were regularly observed 
in DES cases and rarely seen in MYOT and ZASP specimens. These conclusions extend the 
results of an independent myopathological study based on a smaller number of patients [35].
Although differentiation between the MFM subtypes on the basis of clinical/pathological 
characteristics may sometimes be difficult, the awareness of clinical, imaging and 
pathological differences based on studies of representative groups of patients is important 
for further development of diagnostic criteria and subtype-specific treatments. This study 
refines clinical features, muscle imaging and pathological data of three subtypes of MFM 
and shows close similarity between patients with MYOT and ZASP mutations and a 
significant distinction between the late- and the earlier-onset myofibrillar myopathy caused 
by mutations in DES.
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The inability to identify mutations in a small number of our patients may reflect the fact that 
there are other unknown genes also causing the MFM phenotype. Of other possible 
drawbacks, no attempt was made to sequence regulatory gene regions or explore a 
possibility that rare polymorphisms residing in the known MFM genes could in some 
circumstances become pathogenic.
MFM pathogenesis has been under intense investigation, including studies of transgenic 
mice and transfected cell cultures, as well as studies dealing with post-translational protein 
modifications, ectopic protein expression, abnormal protein aggregation and mechanisms of 
aberrant protein clearance (reviewed in [36]). However, the answers to many questions 
regarding the differences in disease phenotypes that may potentially influence subtype-
specific treatments are still lacking. The use of new upcoming technologies will help solve 
these problems and speed up the development of novel therapies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Muscle MRI images in myofibrillar myopathy patients with DES, MYOT, or ZASP 
mutations. In patients with DES (A, B) mutations, selective involvement of the 
semitendinosus (St), gracilis (Gr), sartorius (Sa) and peroneal muscles (Per) occur in the 
early stages of illness. In a patient with a MYOT mutation (C, D), the m. semimembranosus 
(Sm), biceps femoris (Bf), soleus (Sol), and medial gastrocnemius (Mg), are primarily 
involved. Less severe abnormalities are seen in the anterior tibialis and peroneal group. The 
lateral gastrocnemius (Lg) is initially preserved. A similar pattern of involvement is seen in a 
patient with ZASP mutation (E, F). Note the preservation of semitendinosus, sartorius and 
gracilis in patients with MYOT and ZASP mutations. A and B: p.Pro419Ser DES; C and D: 
Ser60Cys MYOT; E and F: p.Ala174Thr ZASP.
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Light microscopy analysis of muscle biopsy samples from myofibrillar myopathy patients 
with DES, MYOT, or ZASP mutations. The most typical lesions in patients carrying 
mutations in DES (A–D) are characterized by thin, discrete patches of amorphous 
eosinophilic (arrow in A) material forming diffuse networks in the cytoplasm. These 
inclusions are best visualized on trichrome stain (B), are devoid of oxidative enzyme activity 
causing a “rubbed-out” appearance (C). Increased desmin (D) immunoreactivity is seen 
under the sarcolemma and within the cytoplasm. In patients with mutations in MYOT (E–H) 
or ZASP (I–L), dense intensely eosinophilic hyaline inclusions are observed on H&E 
staining (thin arrows in E and I). Large numbers of fibers contain red to purple inclusions (F) 
and non-rimmed vacuoles (thick arrows in E and I). On NADH staining (G and K) some 
abnormal areas lack oxidative enzyme activity whereas in other areas oxidative enzyme 
activity is increased. Prominent myotilin-immunoreactive aggregates and dense inclusion 
bodies (H and L) are observed. A–D: p.Ile367Phe DES; E–H: Ser55Phe MYOT; I–L: 
p.Ala165Val ZASP.
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Ultrastructural findings in muscle biopsy samples from myofibrillar myopathy patients with 
DES, MYOT, or ZASP mutations. DES: early lesions consist of dappled electrondense 
structures emanating from the Z-discs (A). In more advanced lesions, a thick reticular 
network of electrondense granulofilamentous material forms in the subsarcolema and 
intermyofibrillar space (B, C); widening and streaming of Z-discs is also observed (B). 
Similar accumulation of granulofilamentous material is observed in cardiac muscle (D). 
MYOT: Dissolved myofibrils with disrupted Z-lines, first focally (E) and later spreading to 
larger areas and resulting in complete myofibrillar disorganization; multiple filamentous 
bundles of Z-disc origin and rod-like bodies (E, F), thin filaments and glycogen granules; 
groups of normal mitochondria surrounding the area of myofibrillar destruction (F); remants 
of filaments of various electron density accumulating into large inclusions (G); collections 
of 15–18 nm filaments are seen among normally looking myofibrils (H). ZASP: streaming 
and widening of the Z-line (I) is followed by sarcomeric disorganization and accumulation 
of filamentous bundles of Z-disc origin and filamentous debris (J); a spheroid inclusion 
composed of remants of filaments and rod-like bodies at the periphery (K); degraded 
material accumulates in autophagic vacuoles (L). A: p.Ile367Phe DES; B and C: 
p.Asp214_Glu245del DES; D: p.Arg406Pro DES E and F: p.Ser55Phe MYOT; G and H: 
p.Ser60Cys MYOT; I and J: p.Ala174Thr ZASP; L: p.Ala165Val ZASP. [Note: Figure 
shown in B is reproduced from Goldfarb L et al. (2010) Desminopathy. In Encyclopedia of 
Life Sciences. John Wiley & Sons Ltd: Chichester. DOI: 
10.1002/9780470015902.a0006173.pub2, with permission from John Wiley & Sons Ltd.]
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Table 1
Number of families/patients affected with myofibrillar myopathy.
Gene No. of affected families No. of patients
DESa 11 18
MYOTb 18 24
ZASPc   3   7
No mutations   3   4
Total 35 53
a
DES mutations identified in Spanish families: p.Arg173_Glu179del, p.Asp214_Glu245del, p.Asn366del, p.Ile367Phe, p.Leu370Pro, p.Leu392-
Pro, p. Arg406Pro, p.Pro419Ser.
b
MYOT mutations identified in Spanish families: p.Ser55Phe, p.Ser60-Cys, p.Ser60Phe, p.Lys36Glu.
c
ZASP mutations identified in Spanish families: p.Ala147Thr, p.Ala165Val.
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Table 2
Summary of clinical manifestations observed in patients with mutations in DES, MYOT or ZASP, and patients 
in which no mutation has been identified.
Mutated gene
DES MYOT ZASP Unknown
Number of families 11   18     3   3
Inheritance
 AD   6     9     3   1
 AR   1     0     0   0
Sporadica   4     9     0   2
Number of studied patients 18   24     7   4
Onset age, mean (yrs) 28   58   56 56
Standard deviation 10.1     8.7     7.1 12.2
Gender
Male   8   13     3   2
Female 10   11     4   2
Initial symptoms
Distal LL   8   19     6   3
Proximal LL   0     3     1   1
Distal and proximal   2     2     0   0
Cardiopathy   8     0     0   0
Advanced illness
Distal LL alone   0     4     0   0
Distal and proximal 4 limbs 18   19     4   4
Neck/trunk weakness   7     1     0   0
Facial weakness   6     0     1   0
Dysphagia   7     2     0   0
Myalgia/stiffness   1   11     2   0
Muscle atrophy 11     7     5   2
Muscle hypertrophy   0     7     0   0
Respiratory weakness   9     3     0   1
Neuropathy   0     1     0   0
Cardiopathy 16 1(?) 1(?)   0
Muscle imaging
Semitendinosus 11/11 2/17 0/5 0/3
Semimembranosus 2/11 15/17 4/5 2/3
Sartorius 11/11 3/17 0/5 1/3
Gracilis 9/11 1/17 0/5 0/3
Vastus intermedius/medialis 3/11 10/17 3/5 2/3
Adductor magnus 2/11 15/17 4/5 2/3
Biceps femoris 1/11 16/17 3/5 2/3
Peroneus 11/11 11/17 2/5 1/3
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Mutated gene
DES MYOT ZASP Unknown
Soleus 3/11 16/17 5/5 1/3
Anterior tibialis 5/11 14/17 1/5 0/3
Medial gastrocnemius 7/11 16/17 5/5 2/3
Lateral gastrocnemius 5/11 10/17 3/5 1/3
Disease outcome
Wheelchair dependency   8     8     2   2
Pacemaker/defibrillator 11     0     0   0
Heart transplantation   2     0     0   0
Sudden death   3     0     0   0
AD, autosomal dominant; AR, autosomal recessive; LL, lower limbs; UL, upper limbs.
The number of studied patients is indicated as denominator if different from the total.
a
The parents of these patients were not available for study, therefore it is unknown if the mutations have arisen de novo.
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Table 3




Number of studied patients 12 20   3
Variation of fiber size 12 20   3
Fibro-fatty tissue proliferation   4 10   3
Vesicular nuclei   3 16   3
Necrosis/phagocytosis   3 13   2
Inflammatory infiltrates   1   6   1
Nemaline-like bodies   3 18   3
Core-like lesions   7 20   3
Type I fiber predominance   8 18   1
Vacuoles 11 17   3
Non-hyaline amorphous inclusions 11 10   3
Hyaline dense inclusions   4 20   3
Spheroid inclusion bodies   2 18   3
Rubbed-out fibers 11   6   0
Electron microscopy
Number of studied patients   9 17   4
Granulofilamentous material   9   8a   1a
Z-line streaming   6 17   4
Tubulofilamentous inclusions   1 14   2
Filamentous bundles   0 17   4
Autophagic vacuoles   7 17   1
Biopsied muscle in DES cases: D (n = 4); B (n = 4); AT (n = 1); G (n = 2); Q (n = 1); in MYOT cases: D (n = 6); B (n = 3); AT (n = 1); G (n = 3); Q 
(n = 6); Sol (n = 1); in ZASP cases: Q (n = 1); not indicated (n = 2), where D, deltoid; B, biceps brachii; AT, anterior tibialis; G, gastrocnemius; Q, 
quadriceps; Sol, soleus.
a
Granulofilamentous material in MYOT and ZASP cases was restricted to small foci in a few fibers.
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